Portfolio Companies News
December 8, 2022Vicore has carried out a directed s...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY O... read more
December 7, 2022Oncopeptides provides update on Pep...
STOCKHOLM — December 07, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug Administration, FDA, has requested a withdrawal of ... read more
December 5, 2022Vicore announces first patient enro...
First randomized clinical investigation with a digital therapy (DTx) to address the psychological symptom burden in pulmonary fibrosis (PF) patientsFirst patient enrolled in US pivotal study; readout expected Q4 2023Supports development of a strong holistic portfolio in rare lung disease Stockho... read more
November 30, 2022Pulmonx Receives Japanese MHLW Appr...
Approval of First Minimally Invasive Treatment Option in Japan that Helps Patients with Advanced Disease Breathe Easier and Have a Better Quality of Life REDWOOD CITY, Calif. & TOKYO--(BUSINESS WIRE)--Nov. 30, 2022-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmon... read more
November 25, 2022Oncopeptides enters into a renewed ...
STOCKHOLM — November 25, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announced that the company has entered into a renewed unsecured loan facility agreem... read more
July 26, 2022Q2 2022 General Market Overview
October 07, 2021HealthCap strengthens senior team
November 29, 2021HealthCap’s 25th company anniversary!
Since the start in 1996, HealthCap funds have invested in 126 portfolio companies.
46 of the portfolio companies have been taken public on fourteen different markets.
31 of the portfolio companies pharmaceutical products have been approved for marketing.
Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more.